The overall incidence of MACE and venous thromboembolic events was similar among patients with IBD treated with vedolizumab vs TNF antagonists (1-year risk of 4.0% vs 2.8%; adjusted HR, 0.90; 95% CI, 0.41-2.01). Here, TNF is linked to inflammatory bowel disease.